Keyvan Ghasami; Fardin Faraji; Masoud Fazeli; Ali Ghazavi; Ghasem Mosayebi
Volume 13, Issue 1 , March 2016, , Pages 16-26
Abstract
Background: Statins, widely used cholesterol-lowering agents, have also been demonstrated to have anti-inflammatory and immunomdulatory effects. Objective: To evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled ...
Read More
Background: Statins, widely used cholesterol-lowering agents, have also been demonstrated to have anti-inflammatory and immunomdulatory effects. Objective: To evaluate the effects of atorvastatin in combination with Interferon-β in the treatment of multiple sclerosis (MS) in a randomized controlled clinical trial. Methods: Multiple sclerosis patients were randomized independently, in a double blind design, into one of two treatment groups. Control group (n=45) received 30 μg/week interferon β-1a via intra-muscular injection. Atorvastatin-treated group (n=50) received interferon β-1a similar to control group in addition to atorvastatin (40 mg/day) for 18-months. All clinical and immunological variables were measured at the baseline and at the end of the study. Results: There was no significant difference between the two groups in the expanded disability status scale scores and the number of gadolinium-enhancing lesions during the 18-month treatment period. After 18 months, the levels of interleukin (IL)-4, IL-10, transforming growth factor-β and serum ferric reducing antioxidant power in the atorvastatin treatment group were significantly higher than the control group. Levels of IL-17, TNF-α and lymphocyte proliferation in the atorvastatin treatment group were significantly lower than the control group. Conclusion: Although combined atorvastatin and interferon-β do not change the clinical course of MS, atorvastatin might have beneficial effects in MS treatment possibly through inducing anti-inflammatory responses.
Zahra Amirghofran; Saeed Malek-Hosseini; Hossein Golmoghaddam; Fathollah Kalantar; Mehdi Shabani
Volume 8, Issue 3 , September 2011, , Pages 159-169
Abstract
Background: A number of medicinal plants have been used to treat various immunological diseases. Nitric oxide (NO) has an important regulatory role in the various types of inflammatory processes. Objective: To investigate the NO modulatory activity of the extracts of several medicinal plants native to ...
Read More
Background: A number of medicinal plants have been used to treat various immunological diseases. Nitric oxide (NO) has an important regulatory role in the various types of inflammatory processes. Objective: To investigate the NO modulatory activity of the extracts of several medicinal plants native to Iran including Dracocephalum kotschyi, Linum persicum, Dionysia termeana, Salvia mirzayanii, Ferulago angulata and Euphorbia cheiradenia. Methods: The methanolic extracts of the plants were prepared and examined for their effects on the NO production by lipopolysaccharide-stimulated mouse macrophages. The level of TNF-α and IL-1β proinflammatory cytokines in the macrophage culture were detected using enzyme-linked immunosorbent assay. Results: All the extracts at concentration of 50 μg/ml demonstrated a significant decrease in NO production (p<0.001) after a 24-hour treatment. This inhibitory effect was also seen after 48 hours. Among the extracts, L. persicum was the strongest extract in reducing the NO production at 1 μg/ml after both 24 and 48-hours (nearly 100% inhibition, p<0.001). S. mirzayanii extract with 66.2 ± 8% inhibition at 50 μg/ml, showed the mildest effects in 48 hour culture. In cytokine release determination, the extract of L. persicum significantly inhibited both TNF-α and IL-1β cytokines production by stimulated macrophages (p<0.001). D. kotschyi, D. termeana and F. angulata decreased secretion of IL-1β from the cells. Conclusion: These results indicate the presence of anti-inflammatory and macrophage inhibitory substances in these plants.